Cas

Collective Audience to Acquire BeOp, Adding Unique AI-Power, Conversational Advertising and Audience Data Offering to AdTech Ecosystem Platform

Retrieved on: 
Friday, March 1, 2024
Adtech (company), Acquisition, DMPS, Collective, AI, Data management, Growth, Samsung, DMP, Letter, Communication, Advertising, API, Martech, JV, Range Rover, Cas, Environment, Partnership

The industry’s first SaaS-, services- and marketplace-based, AI-powered, performance advertising and data platform for media and brands.

Key Points: 
  • The industry’s first SaaS-, services- and marketplace-based, AI-powered, performance advertising and data platform for media and brands.
  • The platform offers a self-serve interface as well as APIs that enable it to be integrated into any environment.
  • This integration positions Collective Audience at the forefront, offering the unique ability to create exclusive zero and first party segments for media.
  • The acquisition would be consummated pursuant to a definitive acquisition agreement between Collective Audience and BeOp.

Epic Bio Reports New Data on Hypercompact Cas Proteins Optimized for Broad Therapeutic Applicability

Retrieved on: 
Thursday, October 26, 2023
Science, AAV, DCAS, Facioscapulohumeral muscular dystrophy, Biotechnology, FSHD, PAMS, Congress, Dicarboxylic acid, Cell, GEMS, Gene, ESGCT, European Society of Gene and Cell Therapy, Patient, Gene expression, SAN, Vaccine, Cas

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, is presenting new data reflecting advances in its Gene Expression Modulation System (GEMS) platform, alongside additional preclinical data supporting the company’s lead program, EPI-321, in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). These data are being presented at the European Society of Gene and Cell Therapy (ESGCT) 30th Annual Congress taking place October 24-27, 2023, in Brussels, Belgium.

Key Points: 
  • These data are being presented at the European Society of Gene and Cell Therapy (ESGCT) 30th Annual Congress taking place October 24-27, 2023, in Brussels, Belgium.
  • Among the data being presented are new details on Epic’s in-house engineered suite of Cas molecules derived from CasMINI, the smallest Cas protein known to work in human cells.
  • In new data at ESGCT, Epic reports that these three Cas effectors also display greater flexibility in the genetic sequences, called PAMs, that they can target.
  • “These data highlight why GEMS is an unparalleled therapeutic platform, and how our team’s unique expertise is expanding the state of the science in epigenetic editing every day.”

Work Out From Anywhere with FitXR: The Ultimate Fitness Companion

Retrieved on: 
Monday, August 28, 2023
Apps, Applications, Technology, Fitness & Nutrition, Communications, Software, Hardware, Health, Influencer, Consumer Electronics, Exercise, VR, Overalls, Virtual reality, Human, Cas, Combat, Content strategy, Perspiration, Boxing, HIIT

FitXR , the leading VR workout platform with the largest offering of fitness classes, today announced that its on-demand workout library hit a milestone of 1,000 classes.

Key Points: 
  • FitXR , the leading VR workout platform with the largest offering of fitness classes, today announced that its on-demand workout library hit a milestone of 1,000 classes.
  • Now, FitXR’s users have access to over 205 hours of workouts across five different fitness studios: Boxing, Dance, HIIT, Combat and Sculpt.
  • FitXR’s wide range of classes is perfect for those traveling since users can avoid lugging heavy equipment, or searching for a hotel gym while on vacation.
  • With availability in hundreds of countries worldwide, FitXR’s immersive platform brings the gym experience straight to you – no matter where you are.

Epic Bio Named a “Fierce 15” Company by Fierce Biotech

Retrieved on: 
Monday, August 28, 2023
Technology, Research, Genetics, Clinical Trials, Health Technology, Biotechnology, Health, Science, Artificial Intelligence, GEMS, CRISPR, Face, Bio, Health care, DCAS, Clinical trial, Gene expression, FSHD, AAV, Creativity, Organization, Facioscapulohumeral muscular dystrophy, Engineering, Mouse, Muscular dystrophy, Cas, SOLVE, Pharmaceutical industry, Vaccine

Epic Bio , a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, has been named to Fierce Biotech’s 2023 “Fierce 15” list, designating it as one of the most outstanding early-stage biotechnology companies in the industry.

Key Points: 
  • Epic Bio , a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, has been named to Fierce Biotech’s 2023 “Fierce 15” list, designating it as one of the most outstanding early-stage biotechnology companies in the industry.
  • “We are very proud to be recognized by Fierce with this honor.
  • It’s a testament to the power of our epigenetic editing platform and the acumen of our team that we’ve made such exciting progress over the past year,” said Amber Salzman, Ph.D., chief executive officer of Epic Bio.
  • “For the past 21 years, we have assessed hundreds of early-stage companies for inclusion in the 'Fierce 15' special report.

Epic Bio Presents New Data on Epigenetic Editing Platform at CRISPR Frontiers Conference

Retrieved on: 
Thursday, August 17, 2023
Science, Biotechnology, Research, Health, Artificial Intelligence, Health Technology, Technology, Genetics, GEMS, CRISPR, Bio, DCAS, Gene expression, Dicarboxylic acid, AAV, Machine learning, Protein engineering, Cas, Cold Spring Harbor, New York, Vaccine, Cold

Epic Bio , a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today presented new data on its epigenetic editing platform at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers conference, being held August 16-20, 2023, in Cold Spring Harbor, NY.

Key Points: 
  • Epic Bio , a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today presented new data on its epigenetic editing platform at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers conference, being held August 16-20, 2023, in Cold Spring Harbor, NY.
  • Epic’s six poster presentations detail a variety of discoveries that expand upon the capabilities of the company’s powerful Gene Expression Modulation System (GEMS) platform.
  • Epic generated novel Cas effectors even smaller than CasMINI, under 500 amino acids in size, and with improved epigenetic editing activity.
  • The presentations will be made available under the publications section of the Science page on the Epic Bio website.

Precedential US Federal Court Decision Hands SNIPR Biome a win in patent appeal over Rockefeller University for CRISPR-Cas microbial gene editing

Retrieved on: 
Monday, July 17, 2023
CRISPR, United States Court of Appeals for the Federal Circuit, Rockefeller, Therapy, Rockefeller University, European Patent Office, PTAB, United States patent law, AIA, History, Leahy–Smith America Invents Act, Patent, Hearing, European Patent Convention, Court, Knowledge, Bacteria, Cas, Television

The patent interference case focused on one allowed patent application owned by Rockefeller University and five patents owned by SNIPR and was declared by the US Patent Trial and Appeal Board in 2021 in Rockefeller University's favor.

Key Points: 
  • The patent interference case focused on one allowed patent application owned by Rockefeller University and five patents owned by SNIPR and was declared by the US Patent Trial and Appeal Board in 2021 in Rockefeller University's favor.
  • This ruling has now been overturned in favor of SNIPR following a hearing by the United States Court of Appeals for the Federal Circuit in February 2023.
  • a microbiome), demonstrated by the European patent, EP3291679 , titled 'Altering Microbial Populations & Modifying Microbiota' granted by the European Patent Office to SNIPR in 2021.
  • Jasper Clube, Co-founder and Chief Patent Counsel of SNIPR Biome, commented, "SNIPR is delighted with this important decision of the Federal Circuit.

Precedential US Federal Court Decision Hands SNIPR Biome a win in patent appeal over Rockefeller University for CRISPR-Cas microbial gene editing

Retrieved on: 
Monday, July 17, 2023
CRISPR, United States Court of Appeals for the Federal Circuit, Rockefeller, Therapy, Rockefeller University, European Patent Office, PTAB, United States patent law, AIA, History, Leahy–Smith America Invents Act, Patent, Hearing, European Patent Convention, Court, Knowledge, Bacteria, Cas, Television

The patent interference case focused on one allowed patent application owned by Rockefeller University and five patents owned by SNIPR and was declared by the US Patent Trial and Appeal Board in 2021 in Rockefeller University's favor.

Key Points: 
  • The patent interference case focused on one allowed patent application owned by Rockefeller University and five patents owned by SNIPR and was declared by the US Patent Trial and Appeal Board in 2021 in Rockefeller University's favor.
  • This ruling has now been overturned in favor of SNIPR following a hearing by the United States Court of Appeals for the Federal Circuit in February 2023.
  • a microbiome), demonstrated by the European patent, EP3291679 , titled 'Altering Microbial Populations & Modifying Microbiota' granted by the European Patent Office to SNIPR in 2021.
  • Jasper Clube, Co-founder and Chief Patent Counsel of SNIPR Biome, commented, "SNIPR is delighted with this important decision of the Federal Circuit.

CRISPR And Cas Genes Market Research Report 2023 Featuring Top Players - Thermo Fisher Scientific, Editas Medicine, CRISPR Therapeutics, Intellia Therapeutics, and Caribou Biosciences - ResearchAndMarkets.com

Retrieved on: 
Monday, July 10, 2023
Health, Genetics, Huntington's disease, CRISPR, DuPont, Genetic engineering, Prevalence, Bayer, Agriculture, Biotechnology, Gene editing, Research, DSM-IV codes, Pioneer Hi Bred International, Editas Medicine, Intellia Therapeutics, Genetic disorder, Genome, Anti-transglutaminase antibodies, Risk, Cystic fibrosis, Drug discovery, Growth, Therapy, Safety, Cas, World Health Organization, Fine chemical, Vaccine, Medical device, Marketing

The pharmaceutical and biotechnology industries are the major contributors to the growth of the CRISPR and Cas genes market.

Key Points: 
  • The pharmaceutical and biotechnology industries are the major contributors to the growth of the CRISPR and Cas genes market.
  • The CRISPR and Cas genes market is highly competitive, with several key players operating in the market.
  • What are the key micro and macro environmental factors that are impacting the growth of CRISPR And Cas Genes market?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the CRISPR And Cas Genes market worldwide?

Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
Friday, May 19, 2023
Biotechnology, Pharmaceutical, Genetics, Health, XE, CRISPR, Serglycin, Therapy, Gene, Engineering, Gene editing, Eye, Enzyme, Los Angeles Convention Center, Brain, RNA, American Society of Gene and Cell Therapy, Cas9, Annual general meeting, Cell, No Deliverance, Library, Society, Cas, Antibiotics, Book, Vaccine, Scribe

Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, will present data on its X-Editing (XE) technologies today at the 26th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting being held in Los Angeles, Calif. and virtually.

Key Points: 
  • Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, will present data on its X-Editing (XE) technologies today at the 26th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting being held in Los Angeles, Calif. and virtually.
  • The data validate the company’s CRISPR by Design™ approach as well as its XE technology as a potent and flexible platform for gene editing.
  • “Molecular engineering is the foundation of Scribe’s philosophy.
  • The data presented at ASGCT demonstrate that holistically engineering CRISPR-based therapies is critical for achieving the therapeutic profile necessary for safe and effective genetic medicines.

Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines

Retrieved on: 
Thursday, January 5, 2023
Science, Stem Cells, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Fred Hutchinson Cancer Research Center, Symbiosis, Bill & Melinda Gates Foundation, Protein engineering, Charisma House, Gene editing, Global Investors Summit, Ribosome, Research, Mirae Asset Financial Group, DNA, IT University of Copenhagen, Bill, NNF, Viking Global Investors, Cell division, Series, CRISPR, Cas, Novo Nordisk Foundation, Acquisition, Patient, Qatar Investment Authority, QIA, University, Transcription activator-like effector nuclease, Investment, Hematology, Time-invariant system, Engineering, CRISPR/Cpf1, Cell, Vaccine

Proceeds will enable Ensoma to advance the development of its Engenious™ in vivo engineered cell therapy platform and accelerate its pipeline of genomic medicines for immuno-oncology and other therapeutic applications.

Key Points: 
  • Proceeds will enable Ensoma to advance the development of its Engenious™ in vivo engineered cell therapy platform and accelerate its pipeline of genomic medicines for immuno-oncology and other therapeutic applications.
  • The company also announced it has entered into a definitive agreement to acquire Twelve Bio ApS, a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas technology.
  • “Ensoma’s platform will enable the next generation of smart immune cell medicines to address complex diseases.
  • “In addition, Ensoma now has the capital, expertise and committed partners necessary to bring our breakthrough medicines to the clinic.